Sickle Cell Anemia

This Phase 2 clinical research study is evaluating the safety and effectiveness of a once-daily oral investigational medicine that may improve anemia and reduce the need for red blood cell (RBC) transfusions among some patients who are chronically transfused.

The Rivella Laboratory uses lentiviral vectors for modulation of gene expression and gene transfer for the cure of hemoglobinopathies.